Immix Biopharma, Inc. (NASDAQ:IMMX) Given Consensus Rating of “Moderate Buy” by Analysts

Immix Biopharma, Inc. (NASDAQ:IMMX) has been given a consensus rating of “Moderate Buy” by the six analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $19.50.

IMMX has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a research note on Tuesday, April 21st. Mizuho raised their price target on Immix Biopharma from $14.00 to $15.00 and gave the company an “outperform” rating in a research note on Monday, March 30th. Morgan Stanley assumed coverage on Immix Biopharma in a research note on Wednesday, March 25th. They set an “overweight” rating and a $20.00 price target on the stock. Wall Street Zen lowered Immix Biopharma from a “hold” rating to a “sell” rating in a research note on Sunday, March 15th. Finally, Citizens Jmp reiterated a “market outperform” rating and issued a $23.00 target price on shares of Immix Biopharma in a research note on Friday, March 27th.

Immix Biopharma Stock Up 1.3%

Shares of IMMX opened at $8.78 on Friday. The company has a market cap of $477.72 million, a PE ratio of -9.54 and a beta of 0.12. The business has a fifty day moving average of $9.46 and a 200 day moving average of $7.09. Immix Biopharma has a 52-week low of $1.87 and a 52-week high of $11.61.

Immix Biopharma (NASDAQ:IMMX) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. As a group, research analysts anticipate that Immix Biopharma will post -0.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immix Biopharma

Several institutional investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC boosted its holdings in Immix Biopharma by 22.5% in the first quarter. Janus Henderson Group PLC now owns 4,802,002 shares of the company’s stock worth $43,698,000 after acquiring an additional 880,434 shares in the last quarter. Eventide Asset Management LLC acquired a new stake in shares of Immix Biopharma during the fourth quarter worth about $13,331,000. Marshall Wace LLP lifted its holdings in shares of Immix Biopharma by 3,495.4% during the fourth quarter. Marshall Wace LLP now owns 1,978,743 shares of the company’s stock worth $10,349,000 after purchasing an additional 1,923,708 shares during the period. Millennium Management LLC acquired a new stake in shares of Immix Biopharma during the fourth quarter worth about $8,681,000. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in shares of Immix Biopharma during the fourth quarter worth about $7,845,000. Institutional investors and hedge funds own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.